Claims 23 & 49

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 26	FEB 13	CASREACT coverage to be extended
NEWS 27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 30	Feb 26	MEDLINE reloaded with enhancements
NEWS 31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS 32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT

MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:28:50 ON 06 MAR 2007

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:29:01 ON 06 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2007 HIGHEST RN 924962-30-1
DICTIONARY FILE UPDATES: 5 MAR 2007 HIGHEST RN 924962-30-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\5.str





chain nodes :
10 11 12 13 14 15 26
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-11 9-10 11-12 12-13 13-14 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 11-12 12-13 14-15
exact bonds :
7-11 9-10 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Any 26:CLASS 27:Atom
Generic attributes :
15:
Saturation : Unsaturated

Element Count :
Node 15: Limited
C,C6-14

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 12:29:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 379273 TO ITERATE

100.0% PROCESSED 379273 ITERATIONS 2488 ANSWERS
SEARCH TIME: 00.00.03

L2 2488 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 23a.str





chain nodes :
10 11 12 13 14 15 24
ring nodes :
1 2 3 4 5 6 7 8 9

```
chain bonds :
7-11  9-10  11-12  12-13  13-14  14-15
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-9  4-5  5-6  7-8  8-9
exact/norm bonds :
2-7  3-9  7-8  8-9  11-12  12-13  14-15
exact bonds :
7-11  9-10  13-14
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:Any  24:CLASS  25:Atom
Generic attributes :
15:
Saturation              : Unsaturated

Element Count :
Node 15: Limited
    C,C6-14
```

L3 STRUCTURE UPLOADED

```
=> d
L3 HAS NO ANSWERS
L3                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l3 full sub=l2
FULL SUBSET SEARCH INITIATED 12:29:56 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -     1032 TO ITERATE

100.0% PROCESSED     1032 ITERATIONS                          1028 ANSWERS
SEARCH TIME: 00.00.01

L4          1028 SEA SUB=L2 SSS FUL L3

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 23ac.str
```





```
chain nodes :
10  11  12  13  14  15  24  26
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
7-11  9-10  11-12  12-13  13-14  13-26  14-15
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-9  4-5  5-6  7-8  8-9
exact/norm bonds :
2-7  3-9  7-8  8-9  11-12  12-13  13-26  14-15
exact bonds :
7-11  9-10  13-14
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:Any  24:CLASS  25:Atom  26:CLASS
Generic attributes :
15:
Saturation              : Unsaturated
```

Element Count :
Node 15: Limited
C,C6-14

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5 full sub=l4
FULL SUBSET SEARCH INITIATED 12:31:08 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 1028 TO ITERATE

100.0% PROCESSED 1028 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L6 1 SEA SUB=L4 SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 23ab.str





chain nodes :
10 11 12 13 14 15 24 26
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-11 9-10 11-12 12-13 13-14 14-15 14-26
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 11-12 12-13 14-15 14-26
exact bonds :
7-11 9-10 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Any 24:CLASS 25:Atom 26:CLASS
Generic attributes :
15:
Saturation : Unsaturated

Element Count :
Node 15: Limited
C,C6-14

L7 STRUCTURE UPLOADED

```
=> d
L7 HAS NO ANSWERS
L7                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l7 full sub=l4
FULL SUBSET SEARCH INITIATED 12:31:40 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -     1028 TO ITERATE

100.0% PROCESSED     1028 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L8             0 SEA SUB=L4 SSS FUL L7

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 49.str
```



chain nodes :
10 11 12 13 14 15 26 28
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
6-28 7-11 9-10 11-12 12-13 13-14 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 6-28 7-8 8-9 11-12 12-13 14-15
exact bonds :
7-11 9-10 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Any 26:CLASS 27:Atom 28:Atom
Generic attributes :
15:
Saturation : Unsaturated

Element Count :
Node 15: Limited
C,C6-14

L9 STRUCTURE UPLOADED

=> d
L9 HAS NO ANSWERS

L9 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l9 full sub=l2
FULL SUBSET SEARCH INITIATED 12:32:28 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 2488 TO ITERATE

100.0% PROCESSED 2488 ITERATIONS 97 ANSWERS
SEARCH TIME: 00.00.01

L10 97 SEA SUB=L2 SSS FUL L9

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 49a.str





chain nodes :
10 11 12 13 14 15 26 28

```
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
6-28  7-11  9-10  11-12  12-13  13-14  14-15
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-9  4-5  5-6  7-8  8-9
exact/norm bonds :
2-7  3-9  6-28  7-8  8-9  11-12  12-13  14-15
exact bonds :
7-11  9-10  13-14
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:Any  26:CLASS  27:Atom  28:Atom
Generic attributes :
15:
Saturation              : Unsaturated
28:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7

Element Count :
Node 15: Limited
    C,C6-14



L11     STRUCTURE UPLOADED

=> d
L11 HAS NO ANSWERS
L11             STR
```



Structure attributes must be viewed using STN Express query preparation.

=> s l11 full sub=l10
FULL SUBSET SEARCH INITIATED 12:33:50 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED 97 ITERATIONS 89 ANSWERS
SEARCH TIME: 00.00.01

L12 89 SEA SUB=L10 SSS FUL L11

=>
Uploading C:\Program Files\Stnexp\Queries\10509795\claim 49b.str





chain nodes :
10 11 12 13 14 15 26 28
ring nodes :

```
1  2  3  4  5  6  7  8  9
chain bonds :
6-28  7-11  9-10  11-12  12-13  13-14  14-15
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-9  4-5  5-6  7-8  8-9
exact/norm bonds :
2-7  3-9  6-28  7-8  8-9  11-12  12-13  14-15
exact bonds :
7-11  9-10  13-14
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Hydrogen count :
11:>= minimum 0
Connectivity :
11:4 M minimum RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:Any  26:CLASS  27:Atom  28:Atom
Generic attributes :
15:
Saturation              : Unsaturated
28:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System     : Monocyclic

Element Count :
Node 15: Limited
    C,C6-14



L13     STRUCTURE UPLOADED

=> d
L13 HAS NO ANSWERS
L13             STR
```



Structure attributes must be viewed using STN Express query preparation.

=> s l13 full sub=l10
FULL SUBSET SEARCH INITIATED 12:35:04 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED 97 ITERATIONS 89 ANSWERS
SEARCH TIME: 00.00.01

L14 89 SEA SUB=L10 SSS FUL L13

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	420.05	420.26

FILE 'CAPLUS' ENTERED AT 12:35:12 ON 06 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 5 Mar 2007 (20070305/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 12:28:50 ON 06 MAR 2007)

FILE 'REGISTRY' ENTERED AT 12:29:01 ON 06 MAR 2007

```
L1             STRUCTURE UPLOADED
L2          2488 S L1 FULL
L3             STRUCTURE UPLOADED
L4          1028 S L3 FULL  SUB=L2
L5             STRUCTURE UPLOADED
L6             1 S L5 FULL  SUB=L4
L7             STRUCTURE UPLOADED
L8             0 S L7 FULL  SUB=L4
L9             STRUCTURE UPLOADED
L10           97 S L9 FULL  SUB=L2
L11            STRUCTURE UPLOADED
L12           89 S L11 FULL  SUB=L10
L13            STRUCTURE UPLOADED
L14           89 S L13 FULL  SUB=L10
```

FILE 'CAPLUS' ENTERED AT 12:35:12 ON 06 MAR 2007

```
=> s l6
L15            1 L6
```
— not prior art

```
=> s l10
L16            1 L10
```
— ~~USPAT~~ instant app

```
=> s l15 or l16
L17            2 L15 OR L16

=> d ibib abs hitstr l15
```

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:356982 CAPLUS
DOCUMENT NUMBER: 144:412514
TITLE: Preparation of indazoles, benzisoxazoles, and benzisothiazoles as estrogenic agents
INVENTOR(S): Rondot, Benoit; Bonnet, Paule; Duc, Igor; Lafay, Jean; Clerc, Thierry; Duranti, Eric; Puccio, Francois; Blot, Christian; Shields, Jacqueline; Maillos, Philippe
PATENT ASSIGNEE(S): Laboratoire Theramex, Monaco
SOURCE: Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1647549	A1	20060419	EP 2004-292439	20041014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
WO 2006040351	A1	20060420	WO 2005-EP55262	20051014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2004-292439 A 20041014

OTHER SOURCE(S): MARPAT 144:412514
GI


I


II

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The title indazoles, benzisoxazoles, and benzisothiazoles with general formula of I [wherein R1 = H, CF3, (un)substituted -N=CH2, alkyl, Ph, etc.; R2 and R3 = independently H, OH, halo, NO2, CN, etc.; X = O, S, SO, SO2, or (un)substituted NH; Y = a bond, O, S, SO, SO2, CO, etc.; A = (un)substituted cycloalkyl, cycloalkenyl, Ph, or naphthyl; with provisos], or pharmaceutically acceptable salts or stereoisomers thereof were prepared as modulators of estrogen receptors. For example, (4-benzyloxy-2-fluorophenyl)methanone (preparation given) was reacted with hydrazine hydrate, followed by hydrogenolysis in ethanol in the presense of Pd/C and PtO2 to give II. II showed biol. activity with IC50 = 41.8 ± 7.1 nM against human estrogen β receptor. The compds. are useful for the prevention or treatment of estrogenic disorders, such as schizophrenia, neurodegenerative diseases, reproductive disorders, etc. (no data).

IT 883717-53-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of indazoles, benzisoxazoles, and benzisothiazoles as estrogenic agents)

RN 883717-53-1 CAPLUS
CN 1H-Indazole-3-acetonitrile, 6-methoxy-α-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:972059 CAPLUS
DOCUMENT NUMBER: 140:27819
TITLE: Preparation of pyrazole derivatives as JNK inhibitors
INVENTOR(S): Ohi, Norihito; Sato, Nobuaki; Soejima, Motohiro; Doko, Takashi; Terauchi, Taro; Naoe, Yoshimitsu; Motoki, Takafumi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 561 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101968	A1	20031211	WO 2003-JP6777	20030529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2482838	A1	20031211	CA 2003-2482838	20030529
AU 2003241925	A1	20031219	AU 2003-241925	20030529
EP 1510516	A1	20050302	EP 2003-733170	20030529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1656079	A	20050817	CN 2003-812475	20030529
US 2005208582	A1	20050922	US 2003-447948	20030530
US 2005261339	A1	20051124	US 2005-509795	20050225
PRIORITY APPLN. INFO.:			JP 2003-153 A	20030106
			JP 2002-158467 A	20020531
			WO 2003-JP6777 W	20030529

OTHER SOURCE(S): MARPAT 140:27819
GI



I

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The title compds. I [R1 represents (CO)h(NRa)j(CRb:CRc)kAr (wherein Ra, Rb, and Rc each independently represents hydrogen, halogeno, hydroxy, optionally substituted C1-6 alkyl, etc.); Ar = (un)substituted aromatic heterocyclic ring, etc.; h, j, k = 0 or 1; Cy is a 5- or 6-membered aromatic heterocycle; and V represents L-X-Y (wherein L is a single bond, optionally substituted C1-6 alkylene, etc.; X is a single bond, O, CO, etc.; and Y is hydrogen, halogeno, nitro, etc.); n = 0 - 4] are prepared Compds. of this invention in vitro showed IC50 values of 63 nM to 578 nM against JNK-3.

IT 633325-20-9P 633325-21-0P 633325-22-1P
633325-23-2P 633325-25-4P 633325-26-5P
633325-27-6P 633325-28-7P 633325-31-2P
633325-32-3P 633325-33-4P 633325-34-5P
633326-02-0P 633326-03-1P 633326-04-2P
633326-05-3P 633326-06-4P 633326-07-5P
633326-08-6P 633326-09-7P 633326-10-0P
633326-11-1P 633326-12-2P 633326-13-3P
633326-14-4P 633326-15-5P 633326-16-6P
633326-17-7P 633326-18-8P 633326-19-9P
633326-20-2P 633326-21-3P 633326-22-4P
633326-23-5P 633326-24-6P 633326-25-7P
633326-26-8P 633326-27-9P 633326-28-0P
633326-29-1P 633326-30-4P 633326-31-5P
633326-32-6P 633326-33-7P 633326-34-8P
633326-35-9P 633326-36-0P 633326-37-1P
633326-39-3P 633326-40-6P 633326-41-7P
633326-42-8P 633326-43-9P 633326-44-0P
633326-45-1P 633326-46-2P 633326-47-3P
633326-48-4P 633326-49-5P 633326-50-8P
633326-51-9P 633326-52-0P 633326-53-1P
633326-54-2P 633326-55-3P 633326-56-4P
633326-57-5P 633326-58-6P 633326-59-7P
633333-19-4P 633333-20-7P 633333-21-8P
633333-22-9P 633333-23-0P 633333-24-1P
633333-25-2P 633333-26-3P 633333-27-4P
633333-28-5P 633333-29-6P 633333-30-9P
633333-31-0P 633333-32-1P 633333-33-2P
633333-34-3P 633333-35-4P 633333-36-5P
633333-37-6P 633333-38-7P 633333-39-8P
633333-40-1P 633333-41-2P 633334-90-4P
633334-91-5P 633334-92-6P 633334-93-7P
633334-94-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. as JNK inhibitors)

RN 633325-20-9 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-5-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633325-21-0 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[7-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633325-22-1 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633325-23-2 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633325-25-4 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-5-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633325-26-5 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[6-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633325-27-6 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633325-28-7 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(3-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633325-31-2 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633325-32-3 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633325-33-4 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633325-34-5 CAPLUS
CN 1H-Indazole, 3-[(1E)-2-(3-fluorophenyl)ethenyl]-4-methoxy-5-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-02-0 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-03-1 CAPLUS
CN 1H-1,2,4-Triazole-3-propanol, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-04-2 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-05-3 CAPLUS
CN 1H-1,2,4-Triazole-3-propanol, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-06-4 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-07-5 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-08-6 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-09-7 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-10-0 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-11-1 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-12-2 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-15-5 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-16-6 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-(1-methylethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-13-3 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-(1-methylethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 633326-14-4 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-17-7 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-18-8 CAPLUS
CN 1H-1,2,4-Triazole-3-methanol, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-19-9 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-20-2 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-21-3 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl-α-(1-methylethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 633326-22-4 CAPLUS
CN Cyclopropanamine, 1-[5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-23-5 CAPLUS
CN Cyclopropanamine, 1-[5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-24-6 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(2-thienylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-25-7 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(phenylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-26-8 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-27-9 CAPLUS
CN 1H-1,2,4-Triazole-3-ethanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-28-0 CAPLUS
CN 1H-1,2,4-Triazole-3-ethanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-29-1 CAPLUS
CN 1H-Indazole, 5-[5-(3-azetidinyl)-1H-1,2,4-triazol-3-yl]-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-30-4 CAPLUS
CN 1H-Indazole, 5-[5-(3-azetidinyl)-1H-1,2,4-triazol-3-yl]-7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-31-5 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-32-6 CAPLUS
CN 1H-Indazole, 5-(1,5-dimethyl-1H-1,2,4-triazol-3-yl)-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-33-7 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-34-8 CAPLUS
CN 1H-1,2,4-Triazole-3-acetamide, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-35-9 CAPLUS
CN 1H-1,2,4-Triazole-3-acetamide, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-36-0 CAPLUS
CN 1,3,4-Oxadiazole-2-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,α,α-trimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-37-1 CAPLUS
CN 1,3,4-Oxadiazole-2-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-α-(1-methylethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 633326-39-3 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-40-6 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-41-7 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-42-8 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-43-9 CAPLUS
CN 1H-Imidazole-4-methanol, 2-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-44-0 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-45-1 CAPLUS
CN 1H-Imidazole-4-methanol, 2-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-46-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-49-5 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-50-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-47-3 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-48-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 4-amino-5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-2,4-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-51-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 4-amino-5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-2,4-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-52-0 CAPLUS
CN 1H-Indazole, 5-(1H-benzimidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-53-1 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(4-methyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-54-2 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-methyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-55-3 CAPLUS
CN 1H-Indazole, 5-(5-chloro-1H-benzimidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-56-4 CAPLUS
CN 1H-Indazole, 6-fluoro-5-(5-fluoro-1H-benzimidazol-2-yl)-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-57-5 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633326-58-6 CAPLUS
CN 1H-Indazole, 5-(5,6-dichloro-1H-benzimidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633326-59-7 CAPLUS
CN 1H-Indazole,
5-(5-chloro-6-fluoro-1H-benzimidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-19-4 CAPLUS
CN 1,3,4-Oxadiazole-2-methanamine, 5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-20-7 CAPLUS
CN Cyclopropanamine, 1-[5-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-21-8 CAPLUS
CN 1,3,4-Oxadiazole-2-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-22-9 CAPLUS
CN Cyclopropanamine, 1-[5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-23-0 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(4-piperidinyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-24-1 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(3-pyridinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-27-4 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(1-piperidinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-28-5 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, 5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N-methyl-α-(1-methylethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-25-2 CAPLUS
CN Cyclopentanamine, 1-[5-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-26-3 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(4-piperidinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-29-6 CAPLUS
CN 1H-1,2,4-Triazole-5-methanamine, 3-[7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-N,1-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-30-9 CAPLUS
CN 1H-Indazole, 5-(4,5-dihydro-1H-imidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-31-0 CAPLUS
CN 1H-Indazole,
5-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-32-1 CAPLUS
CN 1H-Indazole,
5-(4,5-dihydro-4-methyl-1H-imidazol-2-yl)-6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-33-2 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-tetrahydro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-34-3 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-35-4 CAPLUS
CN 5-Pyrimidinol,
2-[6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-1H-indazol-5-yl]-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-36-5 CAPLUS
CN 1H-Indazole, 5-(4,5-dihydro-1H-imidazol-2-yl)-7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-37-6 CAPLUS
CN 1H-Indazole,
5-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-38-7 CAPLUS
CN 1H-Indazole,
5-(4,5-dihydro-4-methyl-1H-imidazol-2-yl)-7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-39-8 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-tetrahydro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633333-40-1 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633333-41-2 CAPLUS
CN 1H-Indazole, 7-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1,4,5,6-tetrahydro-5-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633334-90-4 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-(1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633334-91-5 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(1-piperidinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633334-92-6 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(3-pyridinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 633334-93-7 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(4-piperidinyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 633334-94-8 CAPLUS
CN 1H-Indazole, 6-fluoro-3-[(1E)-2-(4-fluorophenyl)ethenyl]-5-[5-(4-piperidinylmethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT